METHYLDOPA (methyldopa) by Teva is clinical pharmacology methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Approved for hypertension. First approved in 1986.
Drug data last refreshed 21h ago
CLINICAL PHARMACOLOGY Methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then…
Worked on METHYLDOPA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes